Pre-Effective Amendment to Registration Statement – Securities for a Merger — Form S-4 — SA’33
Filing Table of Contents
Document/Exhibit Description Pages Size
1: S-4/A Pre-Effective Amendment to Registration Statement HTML 15.06M
- Securities for a Merger
2: EX-10.11 Letter Agreement, by and Between Pk Asset HTML 37K
Management Ltd and Nukkleus Inc., Dated September
20, 2021
3: EX-23.1 Consent of Rotenberg Meril Solomon Bertiger & HTML 36K
Guttilla, P.C., Independent Registered Public
Accounting Firm of Nukkleus
4: EX-23.2 Consent of Marcum Asia CPAs LLP, Independent HTML 36K
Registered Public Accounting Firm of Brilliant
10: R1 Document And Entity Information HTML 54K
11: R2 Condensed Consolidated Balance Sheets HTML 173K
12: R3 Condensed Consolidated Balance Sheets HTML 87K
(Parentheticals)
13: R4 Unaudited Condensed Consolidated Statements of HTML 203K
Operations and Comprehensive Loss
14: R5 Unaudited Condensed Consolidated Statements of HTML 47K
Operations and Comprehensive Loss (Parentheticals)
15: R6 Unaudited Condensed Statements of Changes in HTML 166K
Shareholders? Equity (Deficit)
16: R7 Unaudited Condensed Statements of Changes in HTML 40K
Shareholders? Equity (Deficit) (Parentheticals)
17: R8 Unaudited Condensed Consolidated Statements of HTML 180K
Cash Flows
18: R9 The Company History and Nature of The Business HTML 130K
19: R10 Restatement of Previously Filed Financial HTML 99K
Statements
20: R11 Basis of Presentation HTML 44K
21: R12 Summary of Significant Accounting Policies HTML 478K
22: R13 Match Acquisition HTML 141K
23: R14 Intangible Assets HTML 150K
24: R15 Accounts Payable and Accrued Liabilities HTML 93K
25: R16 Share Capital HTML 202K
26: R17 Income Taxes HTML 230K
27: R18 Related Party Transactions HTML 260K
28: R19 Concentrations HTML 100K
29: R20 Segment Information HTML 661K
30: R21 Commitments and Contingencies HTML 75K
31: R22 Subsequent Events HTML 56K
32: R23 Events (Unaudited) Subsequent to the Date of the HTML 54K
Independent Auditors? Report
33: R24 Cost Method Investment HTML 41K
34: R25 Equity Method Investment HTML 76K
35: R26 Restatement of Previously Issued Financial HTML 124K
Statements
36: R27 Initial Public Offering HTML 41K
37: R28 Private Placement HTML 43K
38: R29 Shareholders' Equity HTML 77K
39: R30 Derivative Warrant Liabilities HTML 44K
40: R31 Fair Value Measurements HTML 234K
41: R32 Accounting Policies, by Policy (Policies) HTML 546K
42: R33 Restatement of Previously Filed Financial HTML 97K
Statements (Tables)
43: R34 Summary of Significant Accounting Policies HTML 340K
(Tables)
44: R35 Match Acquisition (Tables) HTML 134K
45: R36 Intangible Assets (Tables) HTML 146K
46: R37 Accounts Payable and Accrued Liabilities (Tables) HTML 91K
47: R38 Share Capital (Tables) HTML 182K
48: R39 Income Taxes (Tables) HTML 226K
49: R40 Related Party Transactions (Tables) HTML 218K
50: R41 Concentrations (Tables) HTML 89K
51: R42 Segment Information (Tables) HTML 654K
52: R43 Equity Method Investment (Tables) HTML 72K
53: R44 Restatement of Previously Issued Financial HTML 122K
Statements (Tables)
54: R45 Fair Value Measurements (Tables) HTML 217K
55: R46 The Company History and Nature of The Business HTML 275K
(Details)
56: R47 Restatement of Previously Filed Financial HTML 61K
Statements (Details) - Schedule of represents the
impacts of the adjustment
57: R48 Summary of Significant Accounting Policies HTML 115K
(Details)
58: R49 Summary of Significant Accounting Policies HTML 48K
(Details) - Schedule of cash balances by
geographic area
59: R50 Summary of Significant Accounting Policies HTML 49K
(Details) - Schedule of revenues are disaggregated
by segment
60: R51 Summary of Significant Accounting Policies HTML 44K
(Details) - Schedule of diluted net income (loss)
per share
61: R52 Match Acquisition (Details) HTML 60K
62: R53 Match Acquisition (Details) - Schedule of HTML 56K
summarizes total consideration transferred
63: R54 Intangible Assets (Details) HTML 48K
64: R55 Intangible Assets (Details) - Schedule of HTML 45K
intangible assets
65: R56 Intangible Assets (Details) - Schedule of HTML 49K
amortization of intangible assets attributable to
future periods
66: R57 Accounts Payable and Accrued Liabilities (Details) HTML 50K
- Schedule of accounts payable and accrued
liabilities
67: R58 Share Capital (Details) HTML 203K
68: R59 Share Capital (Details) - Schedule of common stock HTML 49K
issuable upon exercise of options outstanding
69: R60 Share Capital (Details) - Schedule of stock option HTML 60K
activities
70: R61 Share Capital (Details) - Schedule of nonvested HTML 48K
stock options granted
71: R62 Income Taxes (Details) HTML 45K
72: R63 Income Taxes (Details) - Schedule of net income HTML 46K
(Loss)
73: R64 Income Taxes (Details) - Schedule of income taxes HTML 59K
expense (Benefit)
74: R65 Income Taxes (Details) - Schedule of effective HTML 50K
income tax rate reconciliation
75: R66 Income Taxes (Details) - Schedule of deferred tax HTML 45K
assets
76: R67 Related Party Transactions (Details) HTML 154K
77: R68 Related Party Transactions (Details) - Schedule of HTML 49K
related party transaction
78: R69 Related Party Transactions (Details) - Schedule of HTML 44K
due from affiliates
79: R70 Related Party Transactions (Details) - Schedule of HTML 52K
due to affiliates
80: R71 Concentrations (Details) HTML 62K
81: R72 Concentrations (Details) - Schedule of customer HTML 41K
and supplier revenues
82: R73 Segment Information (Details) - Schedule of HTML 81K
reportable business segments
83: R74 Segment Information (Details) - Schedule of total HTML 43K
assets
84: R75 Commitments and Contingencies (Details) HTML 82K
85: R76 Subsequent Events (Details) HTML 84K
86: R77 Events (Unaudited) Subsequent to the Date of the HTML 72K
Independent Auditors? Report (Details)
87: R78 Summary of Significant Accounting Policies HTML 48K
(Details) - Schedule of cash balances by
geographic area
88: R79 Summary of Significant Accounting Policies HTML 49K
(Details) - Schedule of revenues are disaggregated
by segment
89: R80 Summary of Significant Accounting Policies HTML 44K
(Details) - Schedule of securities that were
excluded from the diluted per share calculation
because the effect of including these potential
shares was antidilutive
90: R81 Cost Method Investment (Details) HTML 43K
91: R82 Equity Method Investment (Details) HTML 65K
92: R83 Equity Method Investment (Details) - Schedule of HTML 97K
the summarized financial information
93: R84 Intangible Assets (Details) - Schedule of HTML 72K
intangible assets
94: R85 Intangible Assets (Details) - Schedule of HTML 49K
amortization of intangible assets attributable to
future periods
95: R86 Accounts Payable and Accrued Liabilities (Details) HTML 48K
- Schedule of accounts payable and accrued
liabilities
96: R87 Share Capital (Details) - Schedule of common stock HTML 71K
issuable upon exercise of options outstanding
97: R88 Share Capital (Details) - Schedule of stock option HTML 62K
activities
98: R89 Share Capital (Details) - Schedule of nonvested HTML 49K
stock options granted
99: R90 Related Party Transactions (Details) - Schedule of HTML 49K
related party transaction
100: R91 Related Party Transactions (Details) - Schedule of HTML 44K
due from related parties
101: R92 Related Party Transactions (Details) - Schedule of HTML 52K
due to related parties
102: R93 Concentrations (Details) - Schedule of customer HTML 42K
and supplier revenues
103: R94 Segment Information (Details) - Schedule of HTML 96K
reportable business segments
104: R95 Segment Information (Details) - Schedule of total HTML 43K
assets
105: R96 Match Acquisition (Details) - Schedule of fair HTML 67K
values of the assets acquired and liabilities
assumed, plus transaction costs
106: R97 Restatement of Previously Issued Financial HTML 52K
Statements (Details) - Schedule of effect of the
restatement on each balance sheet
107: R98 Summary of Significant Accounting Policies HTML 49K
(Details) - Schedule of ordinary shares reflected
in the balance sheets
108: R99 Summary of Significant Accounting Policies HTML 48K
(Details) - Schedule of loss per ordinary share
109: R100 Initial Public Offering (Details) HTML 50K
110: R101 Private Placement (Details) HTML 54K
111: R102 Shareholders' Equity (Details) HTML 74K
112: R103 Derivative Warrant Liabilities (Details) HTML 40K
113: R104 Fair Value Measurements (Details) HTML 42K
114: R105 Fair Value Measurements (Details) - Schedule of HTML 47K
company?s assets and liabilities that are measured
at fair value on a recurring basis
115: R106 Fair Value Measurements (Details) - Schedule of HTML 47K
Level 3 fair value measurements inputs of
company?s warrants at their measurement dates
116: R107 Fair Value Measurements (Details) - Schedule of HTML 44K
fair value of the derivative warrant liabilities
117: R108 Summary of Significant Accounting Policies HTML 45K
(Details) - Schedule of ordinary shares reflected
in the balance sheets
118: R109 Summary of Significant Accounting Policies HTML 39K
(Details) - Schedule of ordinary shares reflected
in the balance sheets (Parentheticals)
119: R110 Summary of Significant Accounting Policies HTML 46K
(Details) - Schedule of loss per ordinary share
120: R111 Fair Value Measurements (Details) - Schedule of HTML 47K
fair value hierarchy of the valuation inputs
121: R112 Fair Value Measurements (Details) - Schedule of HTML 47K
Level 3 fair value measurements inputs
122: R113 Fair Value Measurements (Details) - Schedule of HTML 43K
fair value of the derivative warrant liabilities
125: XML IDEA XML File -- Filing Summary XML 259K
123: XML XBRL Instance -- fs42022a4_nukkleusinc_htm XML 6.96M
124: EXCEL IDEA Workbook of Financial Reports XLSX 217K
6: EX-101.CAL XBRL Calculations -- nukk-20220630_cal XML 136K
7: EX-101.DEF XBRL Definitions -- nukk-20220630_def XML 1.69M
8: EX-101.LAB XBRL Labels -- nukk-20220630_lab XML 2.69M
9: EX-101.PRE XBRL Presentations -- nukk-20220630_pre XML 1.62M
5: EX-101.SCH XBRL Schema -- nukk-20220630 XSD 497K
126: JSON XBRL Instance as JSON Data -- MetaLinks 602± 832K
127: ZIP XBRL Zipped Folder -- 0001213900-22-068679-xbrl Zip 2.16M
‘EXCEL’ — IDEA Workbook of Financial Reports
This is an IDEA Workbook.
11 Previous Filings that this Filing References
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent
10/03/22 Nukkleus Inc. S-4/A 9/30/22 127:38M EdgarAgents LLC/FA
9/29/22 Nukkleus Inc. 8-K:1,9 9/28/22 11:215K EdgarAgents LLC/FA
9/22/22 Nukkleus Inc. 8-K:1,9 9/21/22 11:229K EdgarAgents LLC/FA
5/19/22 Nukkleus Inc. 8-K:1,9 5/17/22 12:812K EdgarAgents LLC/FA
4/15/22 Nukkleus Inc. S-4 114:26M EdgarAgents LLC/FA
2/23/22 Nukkleus Inc. 8-K:1,7,9 2/22/22 15:1M EdgarAgents LLC/FA
10/19/17 Nukkleus Inc. 8-K:1,9 10/17/17 3:27K S2 Filings LLC/FA
10/25/16 Nukkleus Inc. 8-K/A:1,2 5/24/16 2:56K S2 Filings LLC/FA
8/09/16 Nukkleus Inc. 8-K:1,5,9 8/01/16 7:308K S2 Filings LLC/FA
6/03/16 Nukkleus Inc. 8-K:1,3,9 5/27/16 9:625K Blueprint/FA
5/31/16 Nukkleus Inc. 8-K:1,2,3,5 5/24/16 5:528K Issuer Direct/FA
|
↑Top
Filing Submission 0001213900-22-068679 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Wed., May 15, 12:49:26.1am ET 
